This proof of concept study used the preSCRIPT framework to analyze prescription data for approximately 230,000 individuals in the UK Biobank. The goal was to filter and annotate raw prescription records to identify genetic associations with drug therapy length and daily doses.
The analysis found that known genetic associations were successfully replicated for amitriptyline, warfarin, and codeine. For example, CYP2D6 variants linked to amitriptyline therapy length and CYP2C9 variants linked to warfarin dose matched existing knowledge. The study also identified new associations for aspirin therapy length and amlodipine dose, with the amlodipine finding replicated in an independent hold-out set.
No safety concerns, adverse events, or discontinuations were reported in this analysis. Because this is a proof of concept study, the results suggest the preSCRIPT framework may serve as a useful tool for large-scale pharmacogenomics. Readers should note that this early work confirms the method works but does not yet provide definitive clinical guidance for individual patients.